329 related articles for article (PubMed ID: 15562128)
1. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
De Wals P; De Serres G; Niyonsenga T
JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
4. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
[TBL] [Abstract][Full Text] [Related]
6. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
Trotter CL; Ramsay ME; Kaczmarski EB
Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
[TBL] [Abstract][Full Text] [Related]
9. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
Larrauri A; Cano R; García M; Mateo Sd
Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
[TBL] [Abstract][Full Text] [Related]
10. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
11. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
[TBL] [Abstract][Full Text] [Related]
12. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
[TBL] [Abstract][Full Text] [Related]
13. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
[TBL] [Abstract][Full Text] [Related]
14. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
[TBL] [Abstract][Full Text] [Related]
16. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
Pollard AJ; Green C; Sadarangani M; Snape MD
Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
[No Abstract] [Full Text] [Related]
17. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
18. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
Mooney JD; Christie P; Robertson C; Clarke SC
Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.
Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB
Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814
[TBL] [Abstract][Full Text] [Related]
20. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.
Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA;
Clin Infect Dis; 2014 Nov; 59(9):1208-15. PubMed ID: 25069868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
